ネクセラファーマ announced that it had filed an application in South Korea for marketing approval of vamorolone, a treatment for Duchenne muscular dystrophy. The application was disclosed at 3:30 p.m. on 22 October 2026.
ネクセラファーマ announced that it had filed an application in South Korea for marketing approval of vamorolone, a treatment for Duchenne muscular dystrophy.
The disclosure was made through an announcement dated the 28th of the same day, and details of the application can be confirmed on Nikkei Company Information DIGITAL.
Attention will now focus on the progress of the review process in South Korea and the timing of disclosure of the review results.